Diagnostic and Prognostic Performance of Neurofilaments in ALS
There is a need for biomarkers for amyotrophic lateral sclerosis (ALS), to support the diagnosis of the disease, to predict disease progression and to track disease activity and treatment responses. Over the last decade multiple studies have investigated the potential of neurofilament levels, both i...
Main Authors: | Koen Poesen, Philip Van Damme |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-01-01
|
Series: | Frontiers in Neurology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fneur.2018.01167/full |
Similar Items
-
Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
by: Federico Verde, et al.
Published: (2021-06-01) -
Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTLD cases
by: Lieselot Dedeene, et al.
Published: (2019-12-01) -
Fluid biomarkers for amyotrophic lateral sclerosis: a review
by: Katherine E. Irwin, et al.
Published: (2024-01-01) -
Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model
by: Marie Dreger, et al.
Published: (2021-04-01) -
The diagnostic significance of neurofilament heavy chains in cerebrospinal fluid in amyotrophic lateral sclerosis
by: Anastasia V. Vladykina, et al.
Published: (2021-03-01)